Cancer Follow-Up Care: Schedule, Tests, and Late Effects

Cancer follow-up care is the structured program of medical appointments, tests, and evaluations that begins when active treatment ends — and it is one of the most underappreciated aspects of the cancer journey. Many survivors assume that completing chemotherapy, radiation, or surgery means their relationship with the medical system is largely over. It is not. Cancer follow-up care continues for at least five years and serves purposes just as important as treatment itself.

There are 18.1 million cancer survivors currently living in the United States — a number projected to grow to 26.1 million by 2040. Each of those survivors needs a structured plan for what comes next: which tests to get, how often, what late effects to watch for based on their specific treatments, and how to address the psychological challenges that persist long after the final infusion. For an overview of cancer treatments and what to expect during active therapy, see the cancer treatment guide.

18.1M Cancer survivors currently living in the US (NCI, 2022) — projected to grow to 26.1 million by 2040 as early detection and treatments improve

~40% Proportion of cancer survivors who experience late or long-term treatment effects — including fatigue, neuropathy, cardiovascular effects, and cognitive impairment

49–70% Proportion of survivors who report clinically significant fear of cancer recurrence — the most commonly reported unmet need in cancer survivorship (Simard et al., 2013 meta-analysis)

5 years Standard duration of structured follow-up surveillance recommended by ASCO/NCCN for most cancer types after completing curative-intent treatment

What Is Cancer Follow-Up Care?

Cancer follow-up care is the ongoing medical management that begins at the transition from active treatment to survivorship. It has five core purposes:

Early detection of recurrence: Identifying cancer that has returned before symptoms appear — when treatment options remain most effective
Late and long-term effects management: Many treatment toxicities appear months to years after chemotherapy, radiation, or hormonal therapy ends — not during it
Secondary malignancy screening: Some cancer treatments increase the risk of a new, different cancer years or decades later
Psychosocial support: Addressing anxiety, depression, fear of recurrence, cognitive effects, sexual health, and return to work
Health promotion: Lifestyle counseling that reduces recurrence risk and improves long-term health

Who Provides Follow-Up Care?

Model	Who Provides Care	Best For
Oncologist-led	Oncologist continues all surveillance	High-risk patients; complex late effects; first 2–3 years for most patients
PCP-led	Primary care after explicit handoff with written SCP	Low-risk, early-stage survivors 3–5+ years post-treatment; ASCO-recommended for low-risk
Shared care (most recommended)	Oncologist manages cancer surveillance; PCP manages late effects + general health	Most cancer survivors; requires explicit written communication between providers
Survivorship clinic	Multidisciplinary team: oncologist, NP, social worker, rehab specialist, psychologist	Most comprehensive; limited to NCI-designated cancer centers
APP-led	Trained nurse practitioners or PAs	Low-risk survivors; evidence shows equivalent outcomes vs. MD-led for low-risk patients

The Communication Gap That Puts Survivors at Risk

The most common follow-up failure: the oncologist assumes the PCP will manage care after treatment; the PCP assumes the oncologist is still in charge; the patient has no clear owner and falls through with no surveillance. Best practice: at your final active treatment visit, confirm in writing which provider manages each component of your follow-up, and schedule your first post-treatment visit before you leave.

Survivorship Care Plans

A survivorship care plan (SCP) is a written document every patient completing curative-intent cancer treatment should receive. ASCO guidelines recommend SCPs for all patients at this transition — yet only an estimated 20–40% of survivors in the US actually receive one.

What a Complete SCP Contains

Diagnosis summary: Cancer type, stage, date, histology, treating institution
Treatment summary: All chemotherapy drugs, doses, and cycles; radiation sites and total doses; surgery with dates; hormonal/targeted/immunotherapy with start and end dates
Surveillance schedule: Specific tests, frequency, and responsible provider — individualized to your cancer type and stage
Late effects monitoring plan: Which late effects are relevant to the specific treatments received and what screening is recommended and when
Health promotion recommendations: Exercise, diet, weight, alcohol, smoking — specific targets
Psychosocial needs assessment and referrals: Screening tools completed; resources identified
Emergency contact information: Who to call for urgent concerns between visits
Care coordination plan: Which provider manages which component going forward

A SWOG S1415CD randomized trial (Hershman DL et al., JCO 2020) in breast cancer survivors showed that those who received a formal SCP had significantly improved adherence to recommended follow-up visits and surveillance tests compared to those who did not. SCPs work — but you may need to ask for one explicitly.

How to Get a Survivorship Care Plan

Ask your oncologist directly at or before your final active treatment visit: “Can I get a survivorship care plan before I leave?” ASCO provides free SCP templates at asco.org/practice-patients/cancer-survivorship. The Journey Forward SCP builder is a free online tool for patients and care teams. The NCI Office of Cancer Survivorship provides additional patient resources. For other key questions to ask your care team at transition points, see the cancer diagnosis questions guide.

Follow-Up Schedules by Cancer Type

Cancer Type	Visit Frequency	Key Surveillance Tests	Important Notes
Breast cancer	Every 3–6 months × 3 years; 6–12 months years 4–5; annually thereafter	Annual mammography; annual pelvic exam (tamoxifen); DEXA annually if on AI	Routine tumor markers (CA 15-3, CA 27-29, CEA) NOT recommended for asymptomatic surveillance — no OS benefit shown
Colorectal cancer	Every 3–6 months × 2 years; every 6 months to 5 years	CEA every 3–6 months × 5 years; CT chest/abdomen/pelvis every 6–12 months × 5 years; colonoscopy at 1 year, 3 years, then every 5 years	CEA is the one tumor marker routinely recommended — rising CEA can identify curable hepatic or pulmonary metastases
Non-small cell lung cancer	Every 6 months × 2 years; annually thereafter	CT chest every 6 months × 2 years; then annually	No routine PET or brain MRI in asymptomatic surveillance
Prostate cancer	Every 6–12 months × 5 years; annually thereafter	PSA every 6–12 months; bone scan/CT only for rising PSA or symptoms	Biochemical recurrence (post-RP): PSA >0.2 ng/mL × 2; (post-RT): PSA nadir + 2 ng/mL (Phoenix criterion)
Ovarian cancer	Every 2–4 months × 2 years; every 3–6 months to 5 years; annually thereafter	CA-125 at each visit (if elevated pretreatment); CT abdomen/pelvis for rising CA-125	Most relapses occur within 2 years of completing first-line treatment
Endometrial cancer	Every 3–6 months × 2–3 years; then annually	H&P; vaginal vault cytology every 6 months × 2 years (high risk); CA-125 if elevated at diagnosis	Physical exam is often more sensitive than imaging for vaginal vault recurrence

Important principle: Routine CBCs, metabolic panels, and most tumor markers are NOT recommended for asymptomatic surveillance in most cancer types. Symptoms always drive additional workup regardless of schedule. If you develop new symptoms between scheduled visits — pain, dyspnea, neurological changes, unexplained weight loss — do not wait for the next appointment.

cancer follow-up care late effects monitoring and psychosocial support survivorship — Cancer follow-up care addresses not just physical surveillance but the psychological impact of survivorship — including fear of recurrence, anxiety, and cognitive effects that affect up to 70% of cancer survivors.

Late Effects of Cancer Treatment

Late effects are treatment-related toxicities that emerge months to years after treatment ends. Understanding what to watch for based on your specific treatment history is a central goal of follow-up care.

Cardiovascular Effects

Anthracyclines (doxorubicin, epirubicin)

Dose-dependent dilated cardiomyopathy; highest risk with cumulative doxorubicin ≥450–550 mg/m²; may appear 10–20 years after exposure; worsened by prior chest radiation, hypertension, diabetes

Trastuzumab (HER2 therapy)

Reversible cardiomyopathy; not dose-dependent; usually resolves after drug discontinuation + cardiac treatment; requires baseline + periodic echocardiogram monitoring

Chest/mediastinal radiation

Accelerated coronary artery disease, valvular disease, pericardial disease; appears 10–20 years post-RT; highest risk with older mantle field techniques (Hodgkin lymphoma); modern IMRT and cardiac-sparing RT reduce but do not eliminate risk

Monitoring: Echocardiogram at 1 year post-treatment then every 3–5 years (or symptom-driven); annual ECG; aggressive cardiovascular risk factor management. Report any new shortness of breath, leg swelling, or exercise intolerance to your oncologist promptly.

Peripheral Neuropathy (CIPN)

Chemotherapy-induced peripheral neuropathy causes numbness, tingling, and sometimes pain in the hands and feet (glove-stocking distribution). Taxanes (paclitaxel, docetaxel, nab-paclitaxel) cause sensory CIPN that may be permanent in 30–40% of patients. Platinum compounds (cisplatin, oxaliplatin) cause cumulative sensory neuropathy; oxaliplatin additionally causes a distinctive cold-triggered acute neuropathy.

Management: duloxetine 30–60 mg/day has the best evidence for established CIPN pain (ASCO guideline); gabapentin or pregabalin for neuropathic pain; physical therapy for balance and fall prevention. No treatment is proven to prevent CIPN.

Cognitive Effects (“Chemo Brain”)

Cancer-related cognitive impairment (CRCI) affects 20–35% of cancer survivors after chemotherapy, with deficits most commonly in processing speed, working memory, and verbal memory. ASCO 2022 guideline evidence-based interventions: aerobic exercise (most consistently effective) and cognitive training programs. Pharmacologic options are not routinely recommended due to insufficient evidence. For more on personalized supportive care, see the personalized cancer treatment article.

Bone Health

Aromatase inhibitors (AI) cause 2–3% per year bone mineral density loss. AI-associated musculoskeletal syndrome (AIMSS — joint pain, morning stiffness) affects up to 50% of AI users. ADT for prostate cancer causes osteoporosis in 30–50% of patients after 5+ years.

Management: Baseline DEXA scan before starting AI or ADT; repeat annually; zoledronic acid 4 mg IV every 6 months OR denosumab 60 mg SC every 6 months if T-score ≤−2.0 or high fracture risk by FRAX; calcium 1,200 mg/day + vitamin D 800–1,000 IU/day for all patients on AI or ADT.

Hormonal Effects and Premature Menopause

Chemotherapy — particularly alkylating agents — causes premature ovarian insufficiency in 40–90% of women over 40. Non-hormonal management of hot flashes: Venlafaxine 37.5–75 mg/day (first-line ASCO recommendation); gabapentin 300 mg three times daily; oxybutynin 2.5–5 mg twice daily. For genitourinary syndrome of menopause (vaginal dryness, dyspareunia), vaginal lubricants and moisturizers address mild symptoms.

Cancer-Related Fatigue

Cancer-related fatigue (CRF) affects 20–40% of survivors one or more years after treatment ends. It is not relieved by rest and is multifactorial. Before attributing fatigue to CRF, exclude treatable causes: hypothyroidism (TSH), anemia (CBC), depression (PHQ-9), sleep disorders. Exercise is the most evidence-based treatment — 150 min/week moderate aerobic activity (ACSM/ASCO guideline).

Secondary Malignancies

Hodgkin Lymphoma Survivors: Breast Cancer Surveillance

Women who received ≥20 Gy to a chest field containing breast tissue have substantially elevated lifetime breast cancer risk. ASCO/NCCN recommendation: begin annual mammography AND annual breast MRI at age 25 or 8 years after RT, whichever is later — the same schedule used for BRCA1/2 mutation carriers. If you received chest radiation as part of Hodgkin lymphoma treatment, confirm this surveillance schedule with your care team.

Additional secondary malignancy risks: treatment-related myeloid neoplasms (t-AML, t-MDS) — 1–3% cumulative risk 5–10 years after alkylating agent or topoisomerase II inhibitor regimens; annual CBC for high-risk patients. Annual skin surveillance for melanoma survivors and those who received immunosuppressive therapy.

Psychosocial Follow-Up

Fear of Cancer Recurrence

Fear of cancer recurrence (FOR) affects 49–70% of cancer survivors at clinically significant levels (Simard S et al., J Pain Symptom Manage 2013). It is the most commonly reported unmet need in cancer survivorship. Clinical FOR — distinct from healthy vigilance — interferes with daily functioning, relationships, and paradoxically can cause some survivors to avoid surveillance visits altogether.

Evidence-based interventions: Cognitive-behavioral therapy (CBT) — most studied and effective; mindfulness-based cognitive therapy (MBCT); online programs (ConquerFear — tested in RCTs). Tell your care team if fear of recurrence is affecting your quality of life — it is a legitimate medical concern with effective treatments.

Depression and Anxiety Screening

Depression affects 20–30% of cancer survivors; anxiety 25–40%. ASCO 2023 survivorship guideline recommends screening all survivors at each follow-up visit using PHQ-9 (depression), GAD-7 (anxiety), or the NCCN Distress Thermometer (0–10 visual scale). Effective interventions: CBT; SSRIs and SNRIs; aerobic exercise; referral to oncology social workers and psycho-oncologists. For integrative approaches, see the personalized cancer treatment article.

Health Promotion After Cancer

Exercise: 150 min/week moderate aerobic + 2 sessions/week resistance training (ACSM/ASCO 2022); reduces all-cause mortality, recurrence risk, fatigue, depression, and bone loss
Diet: Plant-forward, Mediterranean pattern per WCRF/AICR Cancer Survivorship Recommendations; limit processed meat, sugar-sweetened beverages, alcohol, ultra-processed foods
Weight: Achieve and maintain healthy BMI; obesity associated with worse prognosis in breast cancer; 5–10% weight loss in overweight survivors improves hormonal and metabolic biomarkers
Alcohol: Limit to <1 drink/day for women, <2/day for men; IARC Group 1 carcinogen; post-diagnosis intake associated with worse outcomes in breast cancer
Smoking cessation: Worsens outcomes in all tumor types; increases second primary cancer risk; varenicline + counseling most effective; cessation support at every follow-up visit

For information about exercise and survivorship clinical trials, see the cancer clinical trials article.

Frequently Asked Questions

How often should I see my oncologist after cancer treatment?

Most ASCO and NCCN guidelines recommend follow-up visits every 3–6 months for the first 2–3 years, then every 6–12 months for years 4–5, then annually. The first 2–3 years carry the highest recurrence risk for most solid tumors. Your oncologist will specify your exact schedule in your survivorship care plan. Beyond oncology visits, maintain annual primary care appointments for late effects monitoring and general health screening. Specific additional appointments — cardiology if you received anthracyclines; bone density testing if on AI or ADT — should be scheduled based on your specific treatments. Report any new symptoms between visits; do not wait for the next appointment.

What is a survivorship care plan and how do I get one?

A survivorship care plan (SCP) is a written document summarizing your cancer diagnosis, all treatments received (with drugs, doses, and dates), your personalized follow-up surveillance schedule, the late effects you should monitor based on your specific treatments, health promotion recommendations, and psychosocial resources. ASCO recommends all patients completing curative-intent treatment receive a written SCP. To get one, ask your oncologist directly: “Can I get a survivorship care plan before I leave?” ASCO provides free SCP templates at asco.org/practice-patients/cancer-survivorship. The Journey Forward SCP builder is a free online tool. The NCI Office of Cancer Survivorship provides additional resources.

What late effects of cancer treatment should I watch for?

Late effects depend on which treatments you received. Key effects by treatment: Anthracyclines (doxorubicin) — shortness of breath, ankle swelling, reduced exercise tolerance (cardiac; may appear years later). Taxanes — persistent numbness, tingling, or pain in hands and feet (CIPN; may be permanent in 30–40%). Aromatase inhibitors — joint pain, bone loss (get baseline DEXA; calcium + vitamin D daily). Chest radiation — cardiovascular disease risk 10–20 years later. Alkylating agents — premature menopause (women); rare blood disorders (annual CBC). Any treatment — persistent fatigue, cognitive changes, depression, and anxiety are common and treatable. Your SCP should list the specific late effects relevant to your treatment history.

How do I manage fear of cancer coming back?

Fear of cancer recurrence affects up to 70% of survivors — you are not alone and you are not overreacting. When fear interferes with daily life, relationships, sleep, or causes you to avoid medical appointments, it requires active management. Evidence-based options: cognitive-behavioral therapy (CBT) — most studied and effective; mindfulness-based cognitive therapy (MBCT); online programs like ConquerFear (tested in RCTs with sustained benefit). Tell your team directly: “Fear of recurrence is affecting my quality of life — can you refer me to a psycho-oncologist or oncology social worker?” The NCCN Distress Thermometer (0–10 scale used at visits) identifies when distress warrants additional support.

When does follow-up care transfer from my oncologist to my primary care doctor?

For many low-risk early-stage cancer survivors, the transition occurs at 2–5 years of disease-free survival. The shared care model — oncologist manages cancer-specific surveillance; PCP manages late effects and general health — is most widely recommended. The critical element is that the transition is explicit: both you and your PCP receive a written survivorship care plan specifying who is responsible for what. Do not assume this handoff happens automatically. Ask your oncologist: “Who will be managing my follow-up care going forward, and can you send a care summary to my primary care doctor?” If you are unsure who owns your surveillance, contact your oncologist’s office — gaps in surveillance can delay recurrence detection.

What lifestyle changes reduce my risk of cancer coming back?

The most evidence-supported lifestyle changes: (1) Exercise — 150 min/week moderate aerobic + 2 sessions/week resistance training; reduces recurrence risk by up to 30–40% in breast and colorectal cancer survivors; also most effective intervention for cancer-related fatigue. (2) Maintain healthy body weight — obesity is associated with worse prognosis in breast cancer; 5–10% weight loss improves hormonal and metabolic risk factors. (3) Mediterranean-pattern diet — vegetables, fruits, whole grains, legumes, olive oil, fish; limit processed meat, refined carbohydrates, alcohol. (4) Quit smoking — the most important modifiable risk factor for second primary cancers and cancer-related mortality. (5) Limit alcohol — post-diagnosis alcohol intake is associated with worse outcomes in breast cancer and other alcohol-sensitive tumors. For detailed guidelines, see the NCCN survivorship guidelines.

Hershman DL et al. — SWOG S1415CD survivorship care plan adherence; JCO 2020
Simard S et al. — Fear of cancer recurrence meta-analysis; J Pain Symptom Manage 2013
Armenian SH et al. — ASCO cardio-oncology survivorship guideline; JCO 2017 (updated 2022)
Bower JE et al. — ASCO cancer-related fatigue guideline; JCO 2014 / updated 2022
Loprinzi CL et al. — ASCO CIPN guideline; JCO 2020
Loprinzi CL et al. — ASCO hot flash management; JCO 2021
ASCO Survivorship Guidelines — cognitive function, exercise, psychosocial; 2022–2023
Campbell KL et al. — ACSM/ASCO exercise guidelines; Med Sci Sports Exerc 2022
WCRF/AICR — Cancer survivorship nutrition recommendations; 2022
NCI Office of Cancer Survivorship — cancercontrol.cancer.gov/ocs
ASCO Survivorship Resources — asco.org/practice-patients/cancer-survivorship
NCCN Survivorship Guidelines — nccn.org/guidelines/category_1

This article is for educational purposes only and does not constitute medical advice. Discuss all cancer follow-up care decisions with your oncology care team.

4 thoughts on “Cancer Follow-Up Care: Schedule, Tests, and Late Effects”

Pingback: Cancer Monitoring: Tests, Imaging, and Liquid Biopsy - Horizon Health Guide
Pingback: Cancer Recurrence: Signs, Rates, and Treatment Options - Horizon Health Guide
Pingback: Cancer Survivorship: Life After Cancer Treatment - Horizon Health Guide
Pingback: Cancer Patient Support: Resources, Programs, and Where to Turn - Horizon Health Guide